Topical Transdermal Chemoprevention of Breast Cancer: Where Will Nanomedical Approaches Deliver Us?

References

• Apolinário AC , SalataGC, BiancoAFR, FukumoriC, BiaginiLL. Opening the Pandora’s box of nanomedicine: there is indeed ‘plenty of room at the bottom’. Quim. Nova43(2), 212–225 (2020).
   Web of Science ®Google Scholar
• Barenholz YC . Doxil® – the first FDA-approved nano-drug: lessons learned. J. Control. Rel.160(2), 117–134 (2012).
   PubMed Web of Science ®Google Scholar
• Roche CA , TangR, CoopeySB, HughesKS. Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J.25(2), 190–195 (2019).
   PubMed Web of Science ®Google Scholar
• Rotmensz N , DePalo G, FormelliFet al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur. J. Cancer Clin. Oncol.27(9), 1127–1131 (1991).
   Google Scholar
• Prasad V , Diener-WestM. Primary chemoprevention of breast cancer: are the adverse effects too burdensome?CMAJ.187(9), 276–278 (2015).
   PubMed Web of Science ®Google Scholar
• Chun YS , BishtS, ChennaVet al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis33(11), 2242–2249 (2012).
   PubMed Web of Science ®Google Scholar
• Lee O , KhanSA. Novel routes for administering chemoprevention: local transdermal therapy to the breasts. Semin. Oncol.43(1), 107–115 (2016).
   PubMed Web of Science ®Google Scholar
• Lee O , IvancicD, AlluSet al. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation. Cancer Chemother. Pharmacol.76(6), 1235–1246 (2015).
   PubMed Web of Science ®Google Scholar
• Manish M , LynnAM, MishraS. Cytochrome P450 2C9 polymorphism: effect of amino acid substitutions on protein flexibility in the presence of tamoxifen. Comput. Biol. Chem.84, 107166 (2020).
   PubMed Web of Science ®Google Scholar
• Apolinário AC , HauschkeL, NunesJR, LopesLB. Towards nanoformulations for skin delivery of poorly soluble API: what does indeed matter?J. Drug Deliv. Sci. Technol.60, 102045 (2020).
   Web of Science ®Google Scholar
• Cardoso F , KyriakidesS, OhnoSet al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.30(8), 1194–1220 (2019).
   PubMed Web of Science ®Google Scholar
• Rosso KJ , WeissA, ThompsonAM. Are there alternative strategies for the local management of ductal carcinoma in situ?Surg. Oncol. Clin. N. Am.27(1), 69–80 (2018).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF, FerlayJ. Global Cancer Statistics: 2011. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Cuzick J , DeCensiA, ArunBet al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol.12(5), 496–503 (2011).
   PubMed Web of Science ®Google Scholar
• Wattenberg LW . Chemoprophylaxis of carcinogenesis: a review. Cancer Res.26(7), 1520–1526 (1966).
   PubMedGoogle Scholar
• Moon RC , ThompsonHJ, BecciPJet al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res.39(4), 1339–1346 (1979).
   PubMed Web of Science ®Google Scholar
• Sabichi AL , ModianoMR, LeeJJet al. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide 1. Clin. Cancer Res.9(7), 2400–2405 (2003).
   PubMed Web of Science ®Google Scholar
• Decensi A , ZanardiS, ArgustiA, BonanniB, CostaA, VeronesiU. Fenretinide and risk reduction of second breast cancer. Nat. Clin. Pract. Oncol.4(2), 64–65 (2007).
   PubMedGoogle Scholar
• Torrisi R , DecensiA, FormelliF, CameriniT, DePalo G. Chemoprevention of breast cancer with fenretinide. Drugs61(7), 909–918 (2001).
   PubMed Web of Science ®Google Scholar
• Nelson HD , FuR, ZakherB, PappasMMM. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the us preventive services task force. JAMA322(9), 868–886 (2019).
   PubMed Web of Science ®Google Scholar
• Padamsee TJ , HilsM, MuravevaA. Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women’s risk-reduction experiences. BMC Womens Health21(1), 1–12 (2021).
   PubMed Web of Science ®Google Scholar
• Greenwald P , KelloffG, Burch-WhitmanC, KramerBS. Chemoprevention. CA Cancer J. Clin.45(1), 31–49 (1995).
   PubMed Web of Science ®Google Scholar
• Howell A , AndersonAS, ClarkeRBet al. Risk determination and prevention of breast cancer. Breast Cancer Res.16(5), 1–19 (2014).
   Web of Science ®Google Scholar
• Penny LK , WallaceHM. The challenges for cancer chemoprevention. Chem. Soc. Rev.44(24), 8836–8847 (2015).
   PubMed Web of Science ®Google Scholar
• Gabriel EM , JatoiI. Breast cancer chemoprevention. Expert Rev. Anticancer Ther.12(2), 223–228 (2014).
   Web of Science ®Google Scholar
• Wood ME , CukeM, BedrosianI. Prevention therapy for breast cancer: how can we do better?Ann. Surg. Oncol.26, 1970–1972 (2019).
   PubMedGoogle Scholar
• Heisey R , PimlottN, ClemonsM, CummingsS, DrummondN. Women’s views on chemoprevention of breast cancer. Can. Fam. Physician52(5), 624–625 (2006).
   PubMedGoogle Scholar
• Visvanathan K , FabianCJ, BantugEet al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J. Clin. Oncol.37(33), 3152–3165 (2019).
   PubMed Web of Science ®Google Scholar
• Clarke BL , KhoslaS. New selective estrogen and androgen receptor modulators. Curr. Opin. Rheumatol.21(4), 374–379 (2009).
   PubMed Web of Science ®Google Scholar
• Patel HK , BihaniT. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther.186, 1–24 (2018).
   PubMed Web of Science ®Google Scholar
• Xiaob X , KangaH, HuangcdCet al. Potent aromatase inhibitors and molecular mechanism of inhibitory action. Eur. J. Med. Chem.143(1), 426–437 (2018).
   PubMedGoogle Scholar
• Esber N , LeBillan F, Resche-RigonM, LoosfeltH, LombèsM, Chabbert-BuffetN. Ulipristal acetate inhibits progesterone receptor isoform a-mediated human breast cancer proliferation and BCl2-L1 expression. PLoS ONE10(10), 1–19 (2015).
   Web of Science ®Google Scholar
• Dziadkowiec KN , GasiorowskaE, Nowak-MarkwitzE, JankowskaA. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz. Menopauzalny15(4), 215–219 (2016).
   PubMedGoogle Scholar
• De Oliveira VM , AldrighiJM, RinaldiJF. Quimioprevenção do câncer de mama. Rev. Assoc. Med. Bras.52(6), 453–459 (2006).
   PubMedGoogle Scholar
• Zhou G , MyersR, LiYet al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest.108(8), 1167–1174 (2001).
   PubMed Web of Science ®Google Scholar
• Simeone AM , TariAM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell. Mol. Life Sci.61(12), 1475–1484 (2004).
   PubMed Web of Science ®Google Scholar
• Gou Q , GongX, JinJ, ShiJ, HouY. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget8(36), 60704–60709 (2017).
   PubMedGoogle Scholar
• Ching MM , ReaderJ, FultonAM. Eicosanoids in cancer: prostaglandin e2 receptor 4 in cancer therapeutics and immunotherapy. Front. Pharmacol.11, 1–6 (2020).
   PubMed Web of Science ®Google Scholar
• de Oliveira VM , MartinsMM, LucarelliAPet al. Ciclooxigenase-2 nos carcinomas ductais de mama invasivos com componente ductal in situ e no epitélio adjacente. Rev. Bras. Ginecol. Obs.29(6), 310–316 (2007).
   Google Scholar
• Lin NU , WinerEP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res.6(5), 204–210 (2004).
   PubMed Web of Science ®Google Scholar
• Ekyalongo RC , YeeD. Revisiting the IGF-1R as a breast cancer target. Precis. Oncol.1(1), 1–6 (2017).
   PubMedGoogle Scholar
• Flanagan MR , ZaborEC, StempelM, ManginoDA, MorrowM, PilewskieML. Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann. Surg. Oncol.26(7), 2127–2135 (2019).
   PubMed Web of Science ®Google Scholar
• Smith SG , SestakI, ForsterAet al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann. Oncol.27(4), 575–590 (2016).
   PubMed Web of Science ®Google Scholar
• Ropka ME , KeimJ, PhilbrickJT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J. Clin. Oncol.28(18), 3090–3095 (2010).
   PubMed Web of Science ®Google Scholar
• Fisher B , CostantinoJP, WickerhamDLet al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study and other national surgical adjuvant breast and bowel project investigators. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Lee O , IvancicD, ChattertonRT, RademakerAW, KhanSA. In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast. Breast Cancer Targets Ther.3(3), 61–70 (2011).
   PubMedGoogle Scholar
• Goetz MP , KnoxSK, SumanVJet al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101(1), 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Chaturvedi S , GargA. An insight of techniques for the assessment of permeation flux across the skin for optimization of topical and transdermal drug-delivery systems: “Modelling the topical and transdermal drug–delivery systems”. J. Drug Deliv. Sci. Technol.62, 102355 (2021).
   Web of Science ®Google Scholar
• Lee O , PilewskieM, KarlanSet al. Local transdermal delivery of telapristone acetate through breast skin, compared with oral treatment: a randomized double-blind, placebo-controlled Phase II trial. Clin. Pharmacol. Ther.109(3), 728–738 (2021).
   PubMed Web of Science ®Google Scholar
• Al Rabadi L , BerganR. A way forward for cancer chemoprevention: think local. Cancer Prev. Res.10(1), 14–36 (2017).
   PubMed Web of Science ®Google Scholar
• Rouanet P , Linares-CruzG, DravetFet al. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J. Clin. Oncol.23(13), 2980–2987 (2005).
   PubMed Web of Science ®Google Scholar
• Lee O , PageK, IvancicDet al. A randomized Phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clin. Cancer Res.20(14), 3672–3682 (2014).
   PubMed Web of Science ®Google Scholar
• Miller JA , ThompsonPA, HakimIAet al. Safety and feasibility of topical application of limonene as a massage oil to the breast. J. Cancer Ther.03(05), 749–754 (2012).
   Google Scholar
• Benson HAE , GriceJE, MohammedY, NamjoshiS, RobertsMS. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr. Drug Deliv.16(5), 444–460 (2019).
   PubMed Web of Science ®Google Scholar
• Roberts MS , MohammedY, PastoreMNet al. Topical and cutaneous delivery using nanosystems. J. Control. Rel.247, 86–105 (2017).
   PubMed Web of Science ®Google Scholar
• Scheuplein RJ . Permeability of the skin: a review of major concepts and some new developments. J. Invest. Dermatol.67(5), 672–676 (1976).
   Web of Science ®Google Scholar
• Mojeiko G , de BritoM, SalataGC, LopesLB. Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer. Int. J. Pharm.560, 365–376 (2019).
   PubMedGoogle Scholar
• Wong HL , BendayanR, RauthAM, LiY, WuXY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev.59(6), 491–504 (2007).
   PubMed Web of Science ®Google Scholar
• Kamaly N , YameenB, WuJ, FarokhzadOC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev.116(4), 2602–2663 (2016).
   PubMed Web of Science ®Google Scholar
• Li F , DouJ, WeiL, LiS, LiuJ. The selective estrogen receptor modulators in breast cancer prevention. Cancer Chemother. Pharmacol.77(5), 895–903 (2016).
   PubMed Web of Science ®Google Scholar
• Goetz MP , KamalA, AmesMM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther.83(1), 160–166 (2008).
   PubMed Web of Science ®Google Scholar
• Day CM , HickeySM, SongY, PlushSE, GargS. Novel tamoxifen nanoformulations for improving breast cancer treatment: old wine in new bottles. Molecules25(5), 1–27 (2020).
   Web of Science ®Google Scholar
• Ravi PR , AdityaN, KathuriaH, MalekarS, VatsR. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur. J. Pharm. Biopharm.87(1), 114–124 (2014).
   PubMed Web of Science ®Google Scholar
• Elsheikh MA , ElnaggarYSR, GoharEY, AbdallahOY. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int. J. Nanomed.7, 3787–3802 (2012).
   PubMed Web of Science ®Google Scholar
• Singh S , KushwahaAK, VuddandaPR, KarunanidhiP, SinghSK. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res. Int.2013 (584549) (2013).
   Google Scholar
• Khorsand I , KashefR, GhazanfarpourM, MansouriE, DashtiS, KhadivzadehT. The beneficial and adverse effects of raloxifene in menopausal women: a mini review. J. Menopausal Med.24(3), 183 (2018).
   PubMedGoogle Scholar
• Alyafee YA , AlaameryM, BawazeerSet al. Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines. Int. J. Nanomed.13, 199–208 (2018).
   PubMed Web of Science ®Google Scholar
• Bhavsar D , GajjarJ, SawantK. Formulation and development of smart pH responsive mesoporous silica nanoparticles for breast cancer targeted delivery of anastrozole: in vitro and in vivo characterizations. Microporous Mesoporous Mater.279, 107–116 (2019).
   Web of Science ®Google Scholar
• Shavi GV , NayakUY, MaliyakkalNet al. Nanomedicine of anastrozole for breast cancer: physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model. Life Sci.141, 143–155 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang X , McIntoshTJ, GrinstaffMW. Functional lipids and lipoplexes for improved gene delivery. Biochimie94(1), 42–58 (2012).
   PubMed Web of Science ®Google Scholar
• Jayapal JJ , DhanarajS. Exemestane loaded alginate nanoparticles for cancer treatment: formulation and in vitro evaluation. Int. J. Biol. Macromol.105, 416–421 (2017).
   PubMed Web of Science ®Google Scholar
• Kumar A , SawantK. Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics. Cancer Nanotechnol.4(4–5), 57–71 (2013).
   PubMedGoogle Scholar
• To C , KimEH, RoyceDBet al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev. Res.7(7), 698–707 (2014).
   PubMed Web of Science ®Google Scholar
• Chinnaiyan SK , KarthikeyanD, GadelaVR. Development and characterization of metformin loaded pectin nanoparticles for T2 diabetes mellitus. Pharm. Nanotechnol.6(4), 253–263 (2018).
   PubMedGoogle Scholar
• Mughal T . Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics4, 315–323 (2010).
   PubMedGoogle Scholar
• Yang Y , PearsonRM, LeeOet al. Dendron-based micelles for topical delivery of endoxifen: a potential chemo-preventive medicine for breast cancer. Adv. Funct. Mater.24(17), 2442–2449 (2014).
   Web of Science ®Google Scholar
• Costa-fernandez S , MatosJKR, ScheunemannGSet al. Nanostructured lipid carriers containing chitosan or sodium alginate for co-encapsulation of antioxidants and an antimicrobial agent for potential application in wound healing. Int. J. Biol. Macromol.183, 668–680 (2021).
   PubMed Web of Science ®Google Scholar
• Carvalho VF , de LemosDP, VieiraCS, MigottoA, LopesLB. Potential of non-aqueous microemulsions to improve the delivery of lipophilic drugs to the skin. AAPS PharmSciTech.18(5), 1739–1749 (2017).
   PubMed Web of Science ®Google Scholar
• Lin YL , ChenCH, WuHYet al. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. J. Nanobiotechnology.14(1), 1–10 (2016).
   PubMedGoogle Scholar
• Apolinário AC , HauschkeL, NunesJR, LopesLB. Lipid nanovesicles for biomedical applications: ‘What is in a name’?Prog. Lipid Res.82, 101096 (2021).
   PubMed Web of Science ®Google Scholar
• Wu X , PriceGJ, GuyRH. Disposition of nanoparticles and an associated lipophilic permeant following topical application to the skin. Mol. Pharm.6(5), 1441–1448 (2009).
   PubMedGoogle Scholar
• Carvalho VFM , SalataGC, de MatosJKRet al. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. Int. J. Pharm.567, 118460 (2019).
   PubMed Web of Science ®Google Scholar
• Teo WW , SukumarS. Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment. Breast Cancer Res.16(2), 6–8 (2014).
   Google Scholar
• Han SM , BaekJS, KimMS, HwangSJ, ChoCW. Surface modification of paclitaxel-loaded liposomes using d-α-tocopheryl polyethylene glycol 1000 succinate: enhanced cellular uptake and cytotoxicity in multidrug resistant breast cancer cells. Chem. Phys. Lipids213, 39–47 (2018).
   PubMed Web of Science ®Google Scholar
• Liu J , LiJ, LiuNet al. In vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cells. Int. J. Pharm.530(1–2), 291–299 (2017).
   PubMedGoogle Scholar
• Pedrosa LRC , TenHagen TLM, SüssRet al. Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells. Pharm. Res.32(4), 1354–1367 (2015).
   PubMed Web of Science ®Google Scholar
• Ni L , LiY. X. Anti-human epidermal growth factor receptor 2 single-chain fv fragment-decorated dm1 nanoparticles for specific targeting of human epidermal growth factor receptor 2-positive breast tumor cells. J. Biomed. Nanotechnol.17(3), 447–455 (2021).
   PubMed Web of Science ®Google Scholar
• Yang W , VeroniainaH, QiX, ChenP, LiF, KePC. Soft and condensed nanoparticles and nanoformulations for cancer drug delivery and repurpose. Adv. Ther.3(1), 1900102 (2020).
   Google Scholar
• Pepe D , CarvalhoVFM, McCallM, DeLemos DP, LopesLB. Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel. Int. J. Nanomed.11, 2009–2019 (2016).
   PubMed Web of Science ®Google Scholar
• Giacone DV , DartoraVFMC, de MatosJKRet al. Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models. Int. J. Biol. Macromol.165, 1055–1065 (2020).
   PubMed Web of Science ®Google Scholar
• Paolino D , CeliaC, TrapassoE, CilurzoF, FrestaM. Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur. J. Pharm. Biopharm.81(1), 102–112 (2012).
   PubMed Web of Science ®Google Scholar
• Carvalho VFM , MigottoA, GiaconeDVet al. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models. Eur. J. Pharm. Sci.109, 131–143 (2017).
   PubMed Web of Science ®Google Scholar
• Haque T , RahmanKM, ThurstonDE, HadgraftJ, LaneME. Topical therapies for skin cancer and actinic keratosis. Eur. J. Pharm. Sci.77, 279–289 (2015).
   PubMed Web of Science ®Google Scholar
• Bathara M , DateT, ChaudhariD, GhadiR, KucheK, JainS. Exploring the promising potential of high permeation vesicle-mediated localized transdermal delivery of docetaxel in breast cancer to overcome the limitations of systemic chemotherapy. Mol. Pharm.17(7), 2473–2486 (2020).
   PubMedGoogle Scholar
• Kurtz SL , LawsonLB. Liposomes enhance dye localization within the mammary ducts of porcine nipples. Mol. Pharm.16(4), 1703–1713 (2019).
   PubMedGoogle Scholar
• Sundralingam U , ChakravarthiS, RadhakrishnanAK, MuniyandyS, PalanisamyUD. Efficacy of emu oil transfersomes for local transdermal delivery of 4-OH tamoxifen in the treatment of breast cancer. Pharmaceutics12(9), 1–19 (2020).
   Web of Science ®Google Scholar
• Haq A , ChandlerM, Michniak-kohnB. Solubility-physicochemical-thermodynamic theory of penetration enhancer mechanism of action. Int. J. Pharm.575, 118920 (2020).
   PubMedGoogle Scholar
• Li Y , SongJ, TianNet al. Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution. Int. J. Pharm.473(1–2), 316–325 (2014).
   PubMed Web of Science ®Google Scholar
• McClements DJ . Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter.8(6), 1719–1729 (2012).
   Web of Science ®Google Scholar
• Lopes LB . Overcoming the cutaneous barrier with microemulsions. Pharmaceutics6(1), 52–77 (2014).
   PubMedGoogle Scholar
• Nastiti CMRR , PontoT, AbdE, GriceJE, BensonHAE, RobertsMS. Topical nano and microemulsions for skin delivery. Pharmaceutics9(37), 1–25 (2017).
   Google Scholar
• Cevc G , VierlU. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J. Control. Rel.141(3), 277–299 (2010).
   PubMed Web of Science ®Google Scholar
• Shakeel F , BabootaS, AhujaA, AliJ, ShafiqS. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J. Nanobiotechnol.6, 1–11 (2008).
   PubMedGoogle Scholar
• Shakeel F , BabootaS, AhujaA, AliJ, ShafiqS. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. J. Drug Target16(10), 733–740 (2008).
   PubMed Web of Science ®Google Scholar
• Migotto A , CarvalhoVFM, SalataGCet al. Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. Drug Deliv.25(1), 654–667 (2018).
   PubMed Web of Science ®Google Scholar
• Subongkot T . Combined effect of sonophoresis and a microemulsion on the dermal delivery of celecoxib. Drug Deliv.27(1), 1087–1093 (2020).
   PubMed Web of Science ®Google Scholar
• Subongkot T , SirirakT. Development and skin penetration pathway evaluation of microemulsions for enhancing the dermal delivery of celecoxib. Colloids Surfaces B Biointerfaces193, 111103 (2020).
   PubMed Web of Science ®Google Scholar
• Santonocito M , ZappullaC, ViolaSet al. Assessment of a new nanostructured microemulsion system for ocular delivery of sorafenib to posterior segment of the eye. Int. J. Mol. Sci.22(9), 4404 (2021).
   PubMed Web of Science ®Google Scholar
• Shahraeini SS , AkbariJ, SaeediMet al. Atorvastatin Solid lipid nanoparticles as a promising approach for dermal delivery and an anti-inflammatory agent. AAPS PharmSciTech.21(7), 1–10 (2020).
   Web of Science ®Google Scholar
• Passos JS , de MartinoLC, DartoraVFC, de AraujoGLB, IshidaK, LopesLB. Development, skin targeting and antifungal efficacy of topical lipid nanoparticles containing itraconazole. Eur. J. Pharm. Sci.149, 105296 (2020).
   PubMed Web of Science ®Google Scholar
• Müller RH , RadtkeM, WissingSA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev.1, 131–155 (2002).
   Google Scholar
• Gohla S , MaK, MuRH. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm.50, 161–177 (2000).
   PubMed Web of Science ®Google Scholar
• Haider M , AbdinSM, KamalL, OriveG. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics12(3), 288 (2020).
   PubMed Web of Science ®Google Scholar
• Labouta HI , El-KhordaguiLK, KrausT, SchneiderM. Mechanism and determinants of nanoparticle penetration through human skin. Nanoscale3(12), 4989–4999 (2011).
   PubMed Web of Science ®Google Scholar
• Patzelt A , RichterH, KnorrFet al. Selective follicular targeting by modification of the particle sizes. J. Control. Rel.150(1), 45–48 (2011).
   PubMed Web of Science ®Google Scholar
• Nirbhavane P , SharmaG, SinghBet al. Preclinical explorative assessment of celecoxib-based biocompatible lipidic nanocarriers for the management of cfa-induced rheumatoid arthritis in wistar rats. AAPS PharmSciTech19(7), 3187–3198 (2018).
   PubMed Web of Science ®Google Scholar
• Alves GL , TeixeiraFV, BiancaPet al. Preformulation and characterization of raloxifene - loaded lipid nanoparticles for transdermal administration. Drug Deliv. Transl. Res. doi: 10.1007/s13346-021-00949-y (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Üner M , YenerG, ErgüvenM. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. Mater. Sci. Eng. C.103, 109874 (2019).
   PubMed Web of Science ®Google Scholar
• Harivardhan Reddy L , VivekK, BakshiN, MurthyRSR. Tamoxifen citrate loaded solid lipid nanoparticles (SLN™): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm. Dev. Technol.11(2), 167–177 (2006).
   PubMed Web of Science ®Google Scholar
• Jones M , LerouxJ. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm.48(2), 101–111 (1999).
   PubMed Web of Science ®Google Scholar
• Deng P , TengF, ZhouFet al. Y-shaped methoxy poly(ethylene glycol)-block-poly(epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. Mater. Sci. Eng. C.78, 296–304 (2017).
   PubMed Web of Science ®Google Scholar
• Orienti I , ZuccariG, FalconiM, TetiG, IllingworthNA, VealGJ. Novel micelles based on amphiphilic branched PEG as carriers for fenretinide. Nanomedicine8(6), 880–890 (2012).
   PubMed Web of Science ®Google Scholar
• Has C , PanS. Vesicle formation mechanisms: an overview. J. Liposome Res.2104, 1–39 (2020).
   Google Scholar
• Touitou E , DayanN, BergelsonL, GodinB, EliazM. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Rel.65(3), 403–418 (2000).
   PubMed Web of Science ®Google Scholar
• Jain S , JainP, UmamaheshwariRB, JainNK. Transfersomes — a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev. Ind. Pharm.29, 1013–1026 (2003).
   PubMed Web of Science ®Google Scholar
• Song CK , BalakrishnanP, ShimC, ChungS, ChongS, KimD. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surfaces B Biointerfaces92, 299–304 (2012).
   PubMed Web of Science ®Google Scholar
• Babaie S , DelBakhshayesh AR, HaJW, HamishehkarH, KimKH. Invasome: a novel nanocarrier for transdermal drug delivery. Nanomaterials10(2), 1–12 (2020).
   Web of Science ®Google Scholar
• Duangjit S , ObataY, SanoHet al. Menthosomes, novel ultradeformable vesicles for transdermal drug delivery: optimization and characterization. Biol. Pharm. Bull.35(10), 1720–1728 (2012).
   PubMed Web of Science ®Google Scholar
• Cevc G , BlumeG. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochium. Biophys. Acta.1104(1), 226–232 (1992).
   PubMed Web of Science ®Google Scholar
• Tiwari R , PathakK. Statins therapy: a review on conventional and novel formulation approaches. J. Pharm. Pharmacol.63(8), 983–998 (2011).
   PubMed Web of Science ®Google Scholar
• Mahmoud MO , AboudHM, HassanAH, AliAA, JohnstonTP. Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. J. Control. Rel.254, 10–22 (2017).
   PubMed Web of Science ®Google Scholar
• Mahmood S , TaherM, MandalUK. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. Int. J. Nanomed.9, 4331–4346 (2014).
   PubMed Web of Science ®Google Scholar
• Alhakamy NA , FahmyUA, AhmedOAA. Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene. PLoS ONE14(12), 1–13 (2019).
   Web of Science ®Google Scholar
• Sarwa KK , SureshPK, DebnathM, AhmadMZ. Tamoxifen citrate loaded ethosomes for transdermal drug–delivery system: preparation and characterization. Curr. Drug Deliv.10(4), 466–476 (2013).
   PubMed Web of Science ®Google Scholar
• Jukanti R , SheelaS, BandariS, VeerareddyPR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J. Pharm. Sci.101(7), 2271–2280 (2012).
   PubMedGoogle Scholar
• Payne NI , TimminsP, AmbroseCV, WardMD, RidgwayF. Proliposomes: a novel solution to an old problem. J. Pharm. Sci.75(4), 325–329 (1986).
   PubMed Web of Science ®Google Scholar
• Singh B , YangS, KrishnaA, SridharS. Nanoparticle formulations of poly(adp-ribose) polymerase inhibitors for cancer therapy. Front. Chem.8, 1–11 (2020).
   PubMed Web of Science ®Google Scholar
• Pathade AD , KommineniN, BulbakeU, ThummarMM, SamanthulaG, KhanW. Preparation and comparison of oral bioavailability for different nano-formulations of olaparib. AAPS PharmSciTech20(7), 1–13 (2019).
   Web of Science ®Google Scholar
• Marshall SM . 60 years of metformin use: a glance at the past and a look to the future. Diabetologia60(9), 1561–1565 (2017).
   PubMed Web of Science ®Google Scholar
• Yu X , JinY, DuLet al. Transdermal cubic phases of metformin hydrochloride: in silico and in vitro studies of delivery mechanisms. Mol. Pharm.15(8), 3121–3132 (2018).
   PubMedGoogle Scholar
• Bragagni M , MenniniN, MaestrelliFet al. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv.19(7), 354–361 (2012).
   PubMed Web of Science ®Google Scholar
• Sinha A , SureshPK. Enhanced induction of apoptosis in hacat cells by luteolin encapsulated in pegylated liposomes—role of caspase-3/caspase-14. Appl. Biochem. Biotechnol.188(1), 147–164 (2019).
   PubMed Web of Science ®Google Scholar
• Abidin L , MujeebM, ImamSS, AqilM, KhuranaD. Enhanced transdermal delivery of luteolin via non-ionic surfactant-based vesicle: quality evaluation and anti-arthritic assessment. Drug Deliv.23(3), 1079–1084 (2016).
   PubMed Web of Science ®Google Scholar
• Letchford K , BurtH. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm.65(3), 259–269 (2007).
   PubMed Web of Science ®Google Scholar
• Guterres SS , AlvesMP, PohlmannAR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights2, 147–157 (2007).
   PubMedGoogle Scholar
• Alvarez-Román R , NaikA, KaliaYN, GuyRH, FessiH. Skin penetration and distribution of polymeric nanoparticles. J. Control. Rel.99(1), 53–62 (2004).
   PubMed Web of Science ®Google Scholar
• Gomathi T , SudhaPN, FlorenceJAK, VenkatesanJ, AnilS. Fabrication of letrozole formulation using chitosan nanoparticles through ionic gelation method. Int. J. Biol. Macromol.104, 1820–1832 (2017).
   PubMed Web of Science ®Google Scholar
• Graves RA , LedetGA, GlotserEY, MitchnerDM, BostanianLA, MandalTK. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide. Eur. J. Pharm. Sci.76, 1–9 (2015).
   PubMed Web of Science ®Google Scholar
• Yang J , LuoL, OhYet al. Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats. J. Control. Rel.327(5), 456–466 (2020).
   PubMedGoogle Scholar
• Taghizadeh SM , BajgholiS. A new liposomal-drug-in-adhesive patch for transdermal delivery of sodium diclofenac. J. Biomater. Nanobiotechnol.02(05), 576–581 (2011).
   Google Scholar
• Larrañeta E , MccruddenMTC, CourtenayAJ, RyanF. Microneedles: a new frontier in nanomedicine delivery. Pharm. Res.33, 1055–1073 (2016).
   PubMed Web of Science ®Google Scholar
• Xi H , YangY, ZhaoDet al. Transdermal patches for site-specific delivery of anastrozole: in vitro and local tissue disposition evaluation. Int. J. Pharm.391(1–2), 73–78 (2010).
   PubMedGoogle Scholar
• Regenthal R , VoskanianM, BaumannFet al. Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Des. Devel. Ther.12, 3653–3664 (2018).
   PubMed Web of Science ®Google Scholar